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Background. Candidate gene analysis has been frequently used in attempts to understand the pathological processes in-
volved in many aspects of AAA disease.
Methods. This paper sets out a systems approach to reviewing AAA candidate gene analysis studies, whilst, explaining the
key principles and design limitations of this universally applied technique. In addition we have performed a meta-analysis of
six gene polymorphisms (ACE I/D, MTHFRþ 677C> T, MMP91562C> T, Il-1Beta/3953C> T, eNOS 4a/4b &
TIMP1/þ434C> T) reported in multiple case control studies.
Results and conclusions. Three of these polymorphisms were associated with a significant risk of AAA, ACE RR 1.33
[95% CI 1.20e1.48], MTHFR RR 1.14 [1.08e1.21] and MMP9 RR 1.09 [1.01e1.18]. These differences have been
previously reported as equivocal, within a context of contradictory studies and as such this meta-analysis provides new
evidence for their involvement in AAA disease. The plausibility of these findings is discussed within the context of a systems
approach to the pathology of AAA disease.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysm (AAA) is a common life
threatening condition predominantly affecting men
of retirement age. Despite this late presentation it
has been estimated that around 15% of AAA patients
have a family history of AAA disease. The evidence
supporting an inheritable component to AAA disease
has recently been reviewed by Sanford et al. and will
not be discussed in detail.1 This article reviews the im-
pact of candidate gene analysis in understanding
AAA aetiology and uses meta-analysis to help inter-
pret the results of studies to date.
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genetics, 5 University Street, London WC1E 6JF, UK.
E-mail address: rmhaath@ucl.ac.uk (A. R. Thompson)1078–5884/000019 + 12 $32.00/0  2007 European Society for VascuThe Search for Susceptibility Genes
A PubMed literature search with the terms ‘‘aneu-
rysm’’ and ‘‘polymorphism’’ identified 168 studies.
Of these, there were 26 case-control and 5 aneurysm
expansion studies, pertaining to candidate gene anal-
ysis in AAA disease, looking at 78 different single
nucleotide polymorphisms (SNPs). In reviewing the
studies, summarised in Table 1, reporting positive as-
sociations, this paper will consider biological plausi-
bility, population characteristics, concordance with
associated phenotypes (hypertension & other athero-
matous disease processes), the strength of any associ-
ation and the evidence for a gene dose effect. In
addition, we have performed a fixed effects meta-
analysis in six SNPs investigated in more than one
case/control study [ACE I/D, MTHFRþ 677 C> T,
IL1betaþ 3953C> T, TIMP1þ 434C> T, NOS3 4a/
4b, MMP91562C> T].2lar Surgery. Published by Elsevier Ltd. All rights reserved.
Table 1. Summary table of 26 case control (1A), and 5 aorta expansion (1B), candidate gene association studies in AAA disease
Gene SNP Author Year Cases/controls Findings
Table 1A Autoimmunity
/426 ns outside of subgroup analysis
/425 ns
/910 ns
/425 ns outside of subgroup analysis
225 ns
60* [TT genotype in AAA patients
p< 0.05
75 [T allele in AAA patients
p¼ 0.007. Difference in genotype
distribution p< 0.0001
71 ns outside of subgroup analysis
/282 ns
/438* [ T allele in AAA patients p¼ 0.03
44 [ T allele in AAA patients
p< 0.001
/97 ns outside of subgroup analysis
/97 ns outside of subgroup analysis
172* [O32 allele in AAA patients
p¼ 0.002. Difference in genotype
distribution p¼ 0.009
61* Y(GT)<25 allelic frequency in
AAA patients p¼ 0.04
/100 [1082A allele in AAA patients
/ 270* ns
/100 ns
/ 270* ns
/ 270* ns
/100 ns
/425 ns
225 ns
/100 ns
/106 [T allele in AAA patients
p¼ 0.015. Difference in genotype
distribution p¼ 0.012
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ascHLA DQA1, DQB1, DRB1,
DRB3-5
Ogata et al{Ogata, 2006
597 /id}
2006 387
Collagen COL3A1 þ581T>C Ogata et al{Ogata, 2005
30 /id}
2005 387
Elastic fibre biology ABCC6 Q655R, R724K, V725V,
I742V, R1418R
Schulz{Schulz, 2006
592 /id}
2005 133
ELN þ422G>A Ogata et al{Ogata, 2005 30
/id}
2005 387
Ram1 Massart et al{Massart, 2004
62 /id}
2004 99/
Homocysteine
metabolism
MTHFR þ677C>T Brunelli et al{Brunelli, 2000
482 /id}
2000 58/
Strauss et al{Strauss, 2003
588 /id}
2003 63/
Strauss et al{Strauss, 2004
2 /id}
2004 74/
Jones et al{Jones, 2005
82 /id}
2005 428
Sofi et al{Sofi, 2005
594 /id}
2005 438
Ferrara et al{Ferrara, 2006
596 /id}
2006 88/
677C>T, þ1298A>C Strauss et al{Strauss, 2005
595 /id}
2005 106
PON1 108C>T Strauss et al{Strauss, 2005
595 /id}
2005 106
Chemokines CCR5 O32 Ghilardi et al{Ghilardi,
2004 590 /id}
2004 70/
Inflammatory
mediators
HO-1 (GT)n Schillinger et
al{Schillinger, 2002
240 /id}
2002 70/
IL-10 1082G>A, -592C>A Bown et al{Bown, 2003
589 /id}
2003 100
IL-1A -899C>T, þ4845G>T Marculescu et
al{Marculescu, 2005
593 /id}
2005 135
IL-1Beta þ3953C>T Bown et al{Bown, 2003
589 /id}
2003 100
IL-1Beta 511C>T, 31C>T,
þ3954C>T
Marculescu et
al{Marculescu, 2005
593 /id}
2005 135
IL-1RN þ2018C>T Marculescu et
al{Marculescu, 2005
593 /id}
2005 135
IL-6 174G>C Bown et al{Bown, 2003
589 /id}
2003 100
TGF beta1 509T>C Ogata et al{Ogata, 2005
30 /id}
2005 387
Bsu361 Massart et al{Massart, 2004
62 /id}
2004 99/
TNF alpha 308G>A Bown et al{Bown, 2003
589 /id}
2003 100
PAF-AH þ994G>T Unno et al{Unno, 2002
479 /id}
2002 131
E
n
d
o
v
asc
S
u
rg
V
o
l
35,
Jan
u
ary
2008
Mediators of
extracellular matrix
protein degradation
MMP1 1607G>GG Ogata et al{Ogata, 2005
30 /id}
2005 387/425 ns
MMP10 þ180A>G Ogata et al{Ogata, 2005
30 /id}
2005 387/425 ns outside of subgroup analysis
87/425 ns
87/425 ns
1/48 ns
87/425 ns
7/174 ns
87/425 ns
7/174 ns
14/203 Difference in genotype
distribution p¼ 0.03
87/425 ns
7/176 ns
93/163 ns
4/51 ns
87/425 ns outside of subgroup analysis
4/51 [ þ573G allele in AAA males
p¼ 0.0374
87/425 ns
87/425 ns outside of subgroup analysis
50/250* [þ894 T allele in AAA patients
p< 0.0001. Difference in genotype
distribution p< 0.0001
8/410 ns
25/153* ns
6/112* Difference in genotype
distribution in normotensive AAA
patients p¼ 0.001
50/250* [ D allele in AAA patients
p¼ 0.0001. Difference in genotype
distribution p¼ 0.002
(continued on next page)
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AMMP12 82A>G Ogata et al{Ogata, 2005
30 /id}
2005 3
MMP13 77A>G Ogata et al{Ogata, 2005
30 /id}
2005 3
MMP2 1586C>T,-1070T>G,
61G>C, 124G>A,
IVS1þ31C>G,
228G>A, 678G>C,
750C>T, IVS5þ12C>T,
IVS7-18GA, 1149C>T,
1380G>A,
IVS10þ26C>T, IVS12-
4A>G, 1806C>T,
1842C>G, 1860C>T
Hinterseher et
al{Hinterseher, 2006
445 /id}
2005 5
955A>C Ogata et al{Ogata, 2005
30 /id}
2005 3
MMP3 1612 5A/6A Yoon et al{Yoon, 1999
476 /id}
1999 4
Ogata et al{Ogata, 2005
30 /id}
2005 3
MMP9 (CA)n Yoon et al{Yoon, 1999
476 /id}
1999 4
1562C>T Jones et al{Jones, 2003
84 /id}
2003 4
Ogata et al{Ogata, 2005
30 /id}
2005 3
PAI-1 675 4G/5G Yoon et al{Yoon, 1999
476 /id}
1999 4
Rossaak et al{Rossaak,
2000 93 /id}
2000 1
TIMP1 þ323C>T, þ434C>T Wang et al{Wang, 1999 220
/id}
1999 8
þ434C>T, rs2070584 Ogata et al{Ogata, 2005
30 /id}
2005 3
TIMP2 þ306C>T, þ573G>A Wang et al{Wang, 1999
220 /id}
1999 8
rs2009196 Ogata et al{Ogata, 2005
30 /id}
2005 3
TIMP3 1296T>C Ogata et al{Ogata, 2005
30 /id}
2005 3
Nitric oxide pathway NOS3 þ894G>T, 786T>C,
4A/4B
Fatini et al{Fatini, 2005
25 /id}
2005 2
4a/b Kotani et al{Kotani, 2000
586 /id}
2000 5
Rennin angiotensin
system
ACE I/D Hamano et al{Hamano,
1999 585 /id}
1999 1
Pola et al{Pola, 2001
587 /id}
2001 5
Fatini et al{Fatini, 2005
591 /id}
2004 2
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Table 1 (continued)
Gene SNP Author Year Cases/controls Findings
Steroid hormones ER alpha 397T>C, 351A>G Massart et al{Massart, 2004 2004 99/225 ns
99/225 [ þ1730 G allele in AAA patients
p< 0.05. Difference in genotype
distribution p< 0.05
99/225 ns
455 ns
455 ns
455 ns
455 ns
455 ns
460 5G/5G genotype is associated
with [ growth rate
424 ns
58 ns
57 ns
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ER beta þ1730A>G Massart et al{Massart, 2004
62 /id}
2004
PR TaqI Massart et al{Massart, 2004
62 /id}
2004
Table 1B
Mediators of
extracellular matrix
protein degradation
MMP2 1306C>T Eriksson et al{Eriksson,
2005 21 /id}
2005
MMP3 1171 5A>6A Eriksson et al{Eriksson,
2005 21 /id}
2005
MMP9 1562C>T Eriksson et al{Eriksson,
2005 21 /id}
2005
MMP12 82A>G Eriksson et al{Eriksson,
2005 21 /id}
2005
PAI-1 675 4G>5G Eriksson et al{Eriksson,
2005 21 /id}
2005
Jones et al{Jones, 2002
444 /id}
2002
Cystatin C 82G>C, þ148G>A Eriksson et al{Eriksson,
2004 22 /id}
2004
Rennin angiotensin
system
ACE I/D Yeung et al{Yeung, 2002
599 /id}
2002
Lipid metabolism APOE APOE*2,3,4 Gerdes et al{Gerdes, 2000
598 /id}
2000
Abbreviations
- HLA, Human leukocyte antigen
- COL, Collagen
- ELN, Elastin
- PON, Paraoxonase
- CCR, Chemokine Receptor
- HO, Heme-oxygenase
- IL, Interleukine
- TGF, Transforming Growth Factor
- PAF-AH, Platelet-Activating Factor Acetylhydrolase
- MMP, Matrix Metalloproteinase
- PAI, Plasminogen Activator Inhibitor
- TIMP, Tissue Inhibitor of MMP
- NOS, Notric Oxide Synthetase
- ACE, Angiotensin Converting Enzyme
- ER, Oetstrogen Receptor
- PR, Progesterone Receptor
- ns, no statistically significant difference ( p> 0.05)
- RR, Relative Risk.
* Indicates controls and cases have undergone imaging of the aorta.
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Eur J Vasc Endovasc Surg Vol 35, January 2008A systems approach
Candidate gene analysis does not stand up without
a context with which to demonstrate biological plausi-
bility. A systems approach provides that context and
can help in the interpretation of results. An example
of this, in a heterogeneous pathology, can be seen in
Marfan’s syndrome and related disorders. It has
long been known that defects in the fibrillin 1 gene
are largely responsible for the autosomal dominantly
inherited disorder of Marfan’s syndrome.3 However
the discovery that disorders of similar phenotype, in-
cluding some familial thoracic ascending aortic aneu-
rysms, are caused by defects in transforming growth
factor beta receptor (TGFBR) 1 and 2 (Loeys-Dietz
Syndrome), together with animal model work on
TGFb, has led to the realisation that this spectrum of
thoracic aneurysmal diseases are encompassed by
the TGFb pathway.3,4 To assist in the interpretation
of candidate gene analysis in AAA disease, Fig. 1 out-
lines the basic pathways of AAA disease progression
through four stages.
Aneurysm initiation
A number of risk factors for AAA disease are thought
to influence aneurysm initiation. Most of these are
common to other forms of cardiovascular disease,
such as, hypertension (haemodynamic stress), ather-
oma, smoking, male gender, age (time) and a possible
connective tissue disorder. These ‘‘risk factors’’ may
have a greater influence later in aneurysm develop-
ment, or at more than one stage, but for the purpose
of this paper it is convenient to consider them in the
initial stages.
The renin-angiotensin system (RAS) is known to
affect the cardiovascular system at multiple levels.
Despite many functional SNPs in multiple genes be-
ing studied in ischaemic heart disease (IHD),5 only
the angiotensin converting enzyme insertion/deletion
(ACE I/D) polymorphism has been looked at, to date,
in AAA disease. An insertion polymorphism of 287
base pairs (bp), in the ACE gene, is associated with
a 50% decrease in ACE serum and tissue levels,6e8 re-
sulting in lower levels of angiotensin II. The absence
of this 287 bp insertion (the so called ‘‘deletion allele’’)
has been associated with hypertension in men9,10 and
IHD.11 Pola et al.,12 reported a significant increase of
the D allele, with a good allele dose effect (RR. 3.29)
[Fig. 2], in a group of normotensive AAA patients
compared to controls matched for age, sex and risk
factors for atherosclerosis. Surprisingly, this difference
was not seen between hypertensive AAA patients andnormotensive controls, as might have been expected,
and highlights the possibility of type 1 error due to
the small numbers in this study. (This group of hyper-
tensive AAA patients was not included in the meta-
analysis). Two larger case control studies have looked
at the ACE I/D polymorphism in AAA patients. Ha-
mano et al.,13 reported no difference in well-matched
cohorts for age, sex and risk factors for atherosclerotic
disease. Fatini et al.,14 demonstrated a significant dif-
ference in the ACE DD genotype in AAA patients
but the cohorts were poorly matched for hyperten-
sion, dyslipidaemia and smoking habit. The resulting
meta-analysis [Fig. 2A] shows a strong overall associ-
ation between ACE D allele and AAA disease (RR 1.33
[1.20e1.48]).
Massart et al.,15 hypothesised that the delay in on-
set of AAA disease in women is due to the protective
effect of sex steroids. An association between the oes-
trogen receptor bþ 1730 G allele polymorphism and
AAA disease was reported. However, the significance
of this allele on oestrogen receptor activity is un-
known and with such small numbers, this hypothesis
is in need of further evidence.
Aneurysm formation
The homocysteine (Hcy) level is a risk factor for the
development of atherosclerotic disease16 as well as
being able to induce elastolysis in vitro through the ac-
tion of MMP2.17 Methylenetetrahydrofolate reductase
(MTHFR) is the primary enzyme of Hcy metabolism.
The MTHFRþ 677C> T polymorphism causes an
alanine to valine change in the protein which results
in a 70% reduction in enzyme activity, as measured
in vitro, and manifests in vivo as raised Hcy levels.18 Des-
pite obvious connections between AAA disease and
atheromatous disease, a causal role of Hcy in AAA
pathogenesis remains unproven.19 Brunelli et al.,20
demonstrated a higher frequency of the MTHFRþ 677
TT genotype in a small cohort of AAA patients. Three
other studies have also looked at this relationship.
Strauss et al.,21 were able to show a significant increase
in the rare T allele frequency in the AAA group. How-
ever numbers were small and the control group was
not matched for age, sex or parameters of atheroscle-
rotic disease. Sofi et al.,22 and Ferrara et al.,23 were
able to show a higher T allele frequency in 438 and 88
AAA patients versus 438 and 44 controls, respectively.
The study by Ferrara et al.,23 although it reported these
findings, was designed to detect a difference in the
MTHFRþ 677C> T allele frequency between a young
and an old group of patients. For this reason, patients
between the ages of 60e64 were not included, limiting
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Study
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C
Fig. 2. A box whisker plots displaying the results of meta-
analysis of case control studies in AAA disease, ACE I/D
(2A), MTHFRþ 677C> T (2B), and MM91562C> T (2C).
The meta-analysis was performed using the ‘‘Inter-cooled
Stat 9.2 (STB-38:sbe16)’’ package by Sharp and Sterne. [CI,
Confidence Interval].numbers in the study. Interestingly, despite small
numbers, there was an increase in the allele frequency
in the younger cohort of AAA patients ( p< 0.004). Pa-
tients and controls in the study by Sofi et al.,22 were
well matched for age and sex but there was more
than double the preponderance of hypertension, smok-
ing and dyslipidaemia in the AAA cohort. Another
report by Jones et al.,24 was unable to confirm these
findings. Meta-analysis of these studies reveals a signi-
ficant effect in favor of the T allele variant, increasing
the risk of AAA disease (RR 1.14 [95%CI 1.08e1.21])
[Fig. 2B].
Nitric oxide (NO) has multiple effects on vessel
wall biology that could be important in AAA patho-
genesis, including vasodilatation and inhibiting
smooth muscle migration/proliferation.25 The Nitric
Oxide Synthase 3 (NOS3) þ894G> T (Glu298Asp)
polymorphism has been associated with reduced
NO production.26 Fatini et al.,27 reported a highly sig-
nificant difference ( p< 0.0001) in the NOS3þ 894 T al-
lele frequency in a group of 250 AAA patients versus
age/sex matched controls. Significant differences
were also present in atheromatous risk factors be-
tween the patients and controls. The implication is
that the rarer T allele reduces NO tissue levels, con-
tributing to AAA formation. Meta-analysis of NOS3
4a/4b frequency in two case/control studies showed
no significant difference (data not shown).
Chemokines are instrumental to the early response
of the arterial wall to injury. The 32 bp deletion in the
chemokine receptor 5 gene (CCR5) decreases receptor
expression, inhibiting leukocyte recruitment to the
area and reducing any inflammatory infiltrate.28 Ghi-
lardi et al.,29 report an association between AAA dis-
ease and the 32 bp deletion in CCR5. Additional
comparison with peripheral vascular disease (PVD)
and carotid disease patients showed no differences
to the controls, supporting the separation of AAA dis-
ease from other atheromatous diseases. It is proposed
that the CCR5[32 polymorphism results in a decrease
in the Th1 response and in doing so promotes the Th2
response dominant in AAA disease. This differentia-
tion between Th1 and Th2 leukocytes is believe to
be a trigger in determining whether atheromatous
conditions lead to occlusive or aneurysmal disease.30
The role of CCR5 in this is unproven.
By far the greatest area of research interest in AAA
disease of recent years, including candidate gene anal-
ysis, is the role of matrix metalloproteinase’s (MMP)
and their mediators, in elastin degradation. It has be-
come clear that this is a vital step in the early stages of
AAA formation.19 MMP-1, a collagenase, and, MMP-2
and MMP-9, elastases, are implicated in the pathogen-
esis of AAA disease and atherosclerosis.31,32 The
26 A. R. Thompson et al.MMP9 gene has a polymorphism (1562C> T) in the
promoter region, in which the rare T allele is associ-
ated with an almost 2-fold higher promoter activity,
which appears to be due to a weaker binding of the
transcription repressor protein to the promoter.33 It
is therefore a very plausible candidate for AAA for-
mation. Jones et al.,34 reported an increased frequency
in the TT and CT genotypes in 414 AAA cases versus
203 controls. However, Ogata et al.,35 were unable to
demonstrate an association between MMP9 genetic
variation and AAA in two separate populations.
Meta-analysis of these three groups (Fig. 2C) does
confirm a significant, albeit small, allelic dose effect
(RR 1.09 [95% CI 1.01e1.18]).
Unno et al.,36 proposed a link between platelet acti-
vating factor (PAF) induction of MMP1, MMP-2 &
MMP-9 transcription and AAA. The activity of PAF
is controlled by PAF acetylhydrolase (PAF-AH). A
well known polymorphism (þ994G> T) results in
lower enzyme activity and increased levels of PAF.
Previous studies have connected the þ994G> T poly-
morphism to coronary artery disease, stroke and
peripheral arterial disease.37,38 We found a significant
association of the rare T allele and AAA with a
strong genotype dose effect (GTþ TT odds ratio for
AAA of 2.48 (1.36e4.65). Tissue inhibitors of metallo-
proteinases (TIMPs) are major inhibitors of MMPs.
Wang et al.,39 reported a decrease in the rare A allele
for TIMP2þ 573 SNP in AAA patients suggesting it
may be protective against AAA. No explanation of
the potential action of the TIMP2þ 573G>A SNP is
put forward. Although found within the coding re-
gion, this base pair change does not result in an amino
acid change. Meta-analysis of TIMP1þ 434C> T fre-
quency in two case/control studies showed no signif-
icant difference (data not shown).
It is convenient to think of aneurysm growth as
a separate process, with some of the initiating steps
in aneurysm formation being unnecessary for contin-
ued expansion. However, it is likely that many of the
chronic inflammatory processes represented in aneu-
rysm formation are also important to aneurysm
growth and rupture. The influences of inflammatory
mediators are likely to be seen on multiple levels
and for this reason are also less likely to be confined
to AAA. Bown et al.,40 demonstrated a difference in
the IL-10 1082G>A polymorphism in a small group
of AAA patients compared to age and sex matched
controls. IL-10 is a potent anti-inflammatory cytokine,
inhibiting macrophage function and T cell antigen
presentation. The IL-10 1082A allele reduces IL-10
activity.41 This anti-inflammatory action could have
an effect on AAA. Meta-analysis of IL-1bþ 3954C> T
frequency in two case/control studies showed noEur J Vasc Endovasc Surg Vol 35, January 2008significant difference (data not shown). Hemeoxyge-
nase-1 (HO-1) is expressed in vascular smooth muscle
cells and has a potent anti-inflammatory and antioxi-
dant capacity.42 Schillinger et al.,43 reported an associ-
ation between the HO-1 short (<25) GT repeats and
protection from AAA. This association was significant
but showed only a small allele dose effect.
Aneurysm growth
In addition to case-control studies, focusing on likely
pathological processes in AAA growth, actual expan-
sion data has been used in direct association studies
with candidate genes (Table 1B). Largely this has
been performed using the UK small aneurysm trial
data.44 Initial analysis suggested a significant associa-
tion between growth and plasminogen activator in-
hibitor (PAI) 1 -675 4G/5G.45 However, after the
same group later accounted for the non-uniform
nature of aneurysm growth the reported association
was lost.46 Although the UK small aneurysm trial
has produced the most comprehensive growth data
to date (Gerdes et al.47), Yeung et al.48 <60 aneurysms)
it lacks early AAA growth data, between 3 and 4 cm.
With the establishment of AAA screening this data
should become more available and gene association
studies may yet have an influence in this area.
Review of the mechanisms leading to AAA rupture
was considered outside the scope of this paper and
has been extensively reviewed by Choke et al.49
Discussion
Initial attempts to determine the genetic background
of AAA have been on a small scale compared to the
efforts seen in other forms of vascular pathology,
namely hypertension, atheromatous plaque morphol-
ogy and IHD. As a consequence, candidate gene anal-
ysis has often mimicked studies performed in these
pathologies as opposed to being tailored to AAA.
This has resulted in candidate genes for AAA, such
as those identified through gene linkage analysis
50,51 and genes involved in elastic fibre biology, being
largely under investigated. However, studies to date
have provided both some credible associations, as
well as highlighting specific challenges to candidate
gene analysis in AAA.
The distribution of AAA in the population is likely
to reflect multiple common mutations with a small
effect. It is important to realize this when designing
candidate gene studies, as small effects will require
much greater power to detect a difference, especially
if the causal mutation is rare. Fig. 3 displays how
27Candidate Genes in AAAthese factors combine to provide estimates of required
sample size.52 When these factors are taken into ac-
count it is clear that few of the studies in Table 1
were sufficiently powered. For example meta-analysis
of the ACE I/D polymorphism suggests a truer risk
ratio of 1.33 (95% CI 1.20e1.48) for the D allele. Refer-
ring to Fig. 3 it can be seen that despite, a favorable
allele frequency of over 30%, at this hazard ratio about
700 cases and 2100 controls are need for 95% power at
the 80% level.
AAA disease is also problematic for candidate gene
analysis because it is susceptible to confounding influ-
ences of genetic stratification. In other words, it is dif-
ficult to allow for common risk factors which may
have genetic overlap with other disorders. Studies
have gone to various degrees in attempts to exclude,
in particular, atheromatous influences. All AAA can-
didate gene studies have made representation of risk
factors for atheroma in patient and control arms. Sev-
eral have used additional comparison with PVD, IHD
and carotid artery disease cohorts.24,34,43 Although
a direct causal link between AAA disease and ather-
oma has not been proven there is concern that shared
pathways for these pathologies may decrease the
specificity of studies.30 Where associations have al-
ready been made between a SNP and vascular dis-
ease, such as with ACE I/D and MTHFRþ 677C> T,
it is imperative that these confounding factors are ac-
counted for before making associations with AAA.
Common risk factors such as hypertension and smok-
ing are the likely pathways through which such asso-
ciations may exist and it is therefore reasonable to
require that they are approximately matched in con-
trol groups. Secondly there are also notable differ-
ences in the efforts made in studies to exclude AAA
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Fig. 3. Estimated sample size required to detect a relative
risk of AAA disease with a particular statistical power for
mutations of different frequency. Data calculated using the
unmatched case control package in Epi program [Epi Info
(version 6.02) Centres for Disease Control and Prevention,
USA]. Taken from Humphreys et al.,52 with permission.from the control groups. Nine of 26 case/control stud-
ies (Table 1) imaged the aorta in the control group, ex-
cluding a potential 5% falsely identified as not having
AAA disease.53 This may constitute up to a 4.7% loss
in sensitivity prior to any final analysis. In many of
the studies very small effects are seen and it may be
that significant differences have been missed as a
result of this loss of sensitivity.
Initial polymorphism association studies reported
in high impact journals may not stand up to the test
of time and almost always, the final size of the risk as-
sociation is (considerably) smaller than first reported
(the so called ‘‘winners cause’’). It is therefore incum-
bent on workers in the field to follow several key prin-
ciples in reporting studies. The first of these is that
a clear biologically plausible hypothesis should be
given. Secondly, that any observations are repeated
in several independent sets and that where possible
meta-analysis is performed. Study design should set
out any secondary phenotypes and identify potential
confounding factors. The strength of association and
the gene-dose effect should be considered separately.
Finally findings should be confirmed through
experimentation.54
Meta-analysis has been used here as a way of com-
bining and giving an overview of the findings in can-
didate gene studies of AAA disease. This view should
be balanced with an understanding of the limitations
inherent to its methodology. Meta-analysis is the anal-
ysis of already analyzed data, and, should be distin-
guished from the re-analysis of primary data. A
weakness of meta-analysis is in its inability to prop-
erly account for heterogeneity between studies. This
is of particular importance in studies where geo-
graphical location or race may have a large influence.
There are now complex models that can overcome
problems of such heterogeneity, but they rely on large
numbers of studies, which are usually unavailable to
small fields of research.2 Meta-analysis is reliant
largely on published data and as such has the poten-
tial to compound prior publication bias. Candidate
gene analysis is particularly susceptible to this form
of bias where thousands of candidate genes, each
with multiple SNPs, may provide spurious associa-
tions attracting a cherry picking approach both to re-
porting and the publication of positive associations.55
Ways of combating this would include the use of
much larger numbers within studies and encouraging
publication regardless of the statistical significance of
the result. Probably the most useful way forward
would be the use of an online data base, providing
scrutiny for all results and not just those published,
as proposed by the Human Genome Epidemiology
Network.Eur J Vasc Endovasc Surg Vol 35, January 2008
28 A. R. Thompson et al.In its favor, meta-analysis combines studies, in
a weighted manner (usually according to size), pro-
viding the power to both identify the presence of a dif-
ference and also to estimate the size of any difference.
The importance of this ability to pick up small but
significant effects can be seen in other diseases. An
example is seen in the role of the Calpain-10 gene
(CAPN10), SNP-44, in type 2 diabetes (T2DM). Out
of 10 identified gene association studies, containing
3,303 subjects, only one study reported a weak asso-
ciation with T2DM ( p¼ 0.05). However, despite the
seemingly unlikelihood of any association, meta-
analysis identified a moderate, but statistically robust
increased risk of T2DM (OR 1.17 [p¼ 0.02]). This
information was then used to adequately power a
further gene association study with 4,213 subjects,
which confirmed the association identified through
meta-analysis (OR 1.18 [p¼ 0.01]).56 Another example
within cardiovascular disease is that of three SNP’s in
the endothelial Nitric Oxide Synthase gene (eNOS ).
These have been the subject of multiple association
studies looking at coronary heart disease (CHD). Var-
iation in the reported results of these studies made the
interpretation, all but impossible without the use of
meta-analysis. The resulting meta-analysis identified
small but significant associations between two of the
SNPs and CHD, which would not have been found,
in the original case-control studies due to lack of
power.57 Such small but significant differences have
subsequently been used in combination to provide
a prediction of CHD risk.58
Although it is important that meta-analysis is not
used to go beyond the claims of the original data,
this gives a clear example of how meta-analysis can
be used to identify small associations, not possible
within the original studies, and of how these small as-
sociations can still be important tools in predicting
disease. In this article, we have used the risk ratio, ob-
tained through our meta-analysis of ACE I/D, to
demonstrate how AAA gene association studies
have been underpowered. Although the results of
this meta-analysis can also be used to pass comment
on gene associations they should then be confirmed
by adequately-powered studies, free of the types of
bias open to meta-analysis.
The results of our meta-analysis have demonstrated
significant effects in ACE, MTHFR and MMP9. The
ACE insertion polymorphism appears to have the
greatest allele dose effect (RR 1.33[1.20e1.48]). But, it
should be noted that the reported control allele
frequencies are different to those seen in larger popu-
lation studies.59,60 which may have erroneously
increased the size of any effect. In addition, the signi-
ficance of hypertension, as a confounding factor, isEur J Vasc Endovasc Surg Vol 35, January 2008difficult to reconcile in this group. Hypertension is
a recognized risk factor for AAA.61,62 The role of the
RAS in hypertensive AAA patients should now be
the attention of biological studies in an attempt to con-
firm the first meaningful association made through
candidate gene analysis and AAA. Hackman et al.63
reported an association between the use of ACE inhib-
itors and reduced rates of AAA rupture, in a group of
Canadian AAA patients.
In conclusion, candidate gene studies, to date, have
lacked the numbers to discover the small but signifi-
cant associations likely to affect this complex multi-
factorial pathology. Subsequent attempts should
involve collaborations to maximize the power of stud-
ies. The future of gene analysis in AAA disease re-
mains wide open. New platform analysis techniques
are likely to throw up many associations but there is
a danger that much time will be wasted in following
up biologically unsound leads.
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